FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors), JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors)

Therapeutic Areas

NeoplasmsHemic and Lymphatic DiseasesOther Diseases

Active Indication

Adult Acute Myeloblastic LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Syndromes+ [2]

Inactive Indication-

Originator Organization

Hanmi Pharmaceutical Co., Ltd.

Active Organization

Aptose Biosciences, Inc.

Inactive Organization

Hanmi Pharmaceutical Co., Ltd.

License Organization

Aptose Biosciences, Inc.

Hanmi Pharmaceutical Co., Ltd.

Drug Highest PhasePhase 1/2

First Approval Date-

RegulationFast Track (United States), Orphan Drug (United States)

Structure/Sequence

Molecular FormulaC29H33ClN6

InChIKeyFZLSDZZNPXXBBB-KDURUIRLSA-N

CAS Registry2294874-49-8

Clinical Trials associated with Tuspetinib

NCT03850574

/ RecruitingPhase 1/2

A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2 (MDS-IB2), or chronic myelomonocytic leukemia (CMML) that is relapsed or refractory after at least one line of prior therapy, or in study participants with newly diagnosed AML. Tuspetinib will be administered as a single agent or in combination with other drugs (venetoclax or venetoclax plus azacitidine), as specified for each part of the study.

Start Date11 Mar 2019

Sponsor / Collaborator

Aptose Biosciences, Inc.

100 Clinical Results associated with Tuspetinib

100 Translational Medicine associated with Tuspetinib

100 Patents (Medical) associated with Tuspetinib

101

Literatures (Medical) associated with Tuspetinib

01 May 2025·Brain Stimulation

Biophysical effects and neuromodulatory dose of transcranial ultrasonic stimulation

Review

Author: Verhagen, Lennart ; Stagg, Charlotte J ; Naftchi-Ardebili, Kasra ; Nandi, Tulika ; Kop, Benjamin R ; Pauly, Kim Butts

Transcranial ultrasonic stimulation (TUS) has the potential to usher in a new era for human neuroscience by allowing spatially precise and high-resolution non-invasive targeting of both deep and superficial brain regions. Currently, fundamental research on the mechanisms of interaction between ultrasound and neural tissues is progressing in parallel with application-focused research. However, a major hurdle in the wider use of TUS is the selection of optimal parameters to enable safe and effective neuromodulation in humans. In this paper, we will discuss the major factors that determine the efficacy of TUS. We will discuss the thermal and mechanical biophysical effects of ultrasound, which underlie its biological effects, in the context of their relationships with tunable parameters. Based on this knowledge of biophysical effects, and drawing on concepts from radiotherapy, we propose a framework for conceptualising TUS dose.

01 Apr 2025·Journal of Cosmetic Dermatology

A Novel Technology to Boost Natural Production of Hyaluronic Acid in the Skin Tissue: Human Histology Study

Article

Author: Goldberg, David J.

ABSTRACT:

Introduction:

Combining monopolar radiofrequency (RF) with targeted ultrasound (TUS), this study investigated whether these modalities promote facial rejuvenation through the production of hyaluronic acid (HA) in human skin.

Methods:

Seven subjects (51–64 years, BMI 21.1–29.8 kg/m2) were enrolled and divided into three treatment groups in this single‐center study; Group A (n = 3, simultaneous RF + TUS), Group B (n = 3, stand‐alone RF), and control (n = 1, no treatment). Both treated groups underwent four (4) 60‐min treatments on the face delivered 7–14 days apart. Punch biopsies (3 mm in diameter) were collected from the infra‐auricular area at baseline and both follow‐up visits and stained for HA by using hyaluronic acid binding protein. Digital photographs were taken to document changes in visual appearance. Finally, the subjects' comfort and satisfaction were assessed.

Results:

There was a statistically significant (p < 0.05) average increase at 1 month in the HA‐stained area of +112 358.7 μm2 in group A (RF + TUS) representing an increase of 48.65%. The treatment effect peaked at 3 months with an increase of +156 345.2 μm2, corresponding to a 67.69% increase in the HA‐stained area. In Group B, there was no significant difference in the average increase of the HA‐stained area between 1 month (+14 830 μm2) and 3 months (+20 995 μm2) corresponding to a 6.76% and 9.56% increase, respectively. The control samples did not indicate any changes throughout the study. Digital photographs of the RF + TUS group showed both a decrease in rhytids and tighter skin. Therapies were comfortable with no adverse events.

Conclusion:

Overall, this study has shown that the combination treatment of RF + TUS has a more pronounced and sustained effect on facial rejuvenation compared to RF alone. The measurable increase in the production of HA with simultaneous use of RF + TUS peaked at a 3‐month follow‐up, suggesting the gradual advancement of the treatment effect and overall improvement in facial appearance.

Trial Registration:

ClinicalTrials.gov identifier: NCT05987917

01 Apr 2025·JOURNAL OF DAIRY SCIENCE

The association of lung consolidation and respiratory pathogens identified at weaning on the growth performance of beef-on-dairy calves

Article

Author: Renaud, D L ; Felix, T L ; Fernandes, I L B ; Sockett, D ; Cantor, M C ; Welk, A

This observational study evaluated the relationship between lung consolidation (LC) observed at weaning and calf ADG, and the association of pathogen shedding at weaning on ADG in beef × dairy calves up to 238 d. Beef × Holstein calves (n = 143) were sourced from 2 dairies. Calves were managed in 3 cohorts and fed milk replacer and calf starter before weaning. Calves were transported to another facility after weaning and raised in one group, where they were fed calf starter with oat hay and transitioned to a corn silage-based TMR diet. Calf ADG was calculated from arrival to weaning at 61 ± 14 d (period 1), from weaning to 83 ± 21 d (period 2), and from 83 d to 238 ± 21 d (period 3). Thoracic ultrasonography (TUS) was performed at weaning to evaluate if a calf had LC (characterized as TUS+ if ≥1 cm² in one lobe) and to categorize the degree of LC found (none [TUS-], 1-2 cm², or = 3 cm²). Nasopharyngeal swabs were taken from the TUS+ calves and from pair-matched TUS- calves (n = 35 pairs) for pathogen identification by culture at a diagnostic laboratory. A mixed linear regression model assessed the association of LC with calf ADG with LC, period, period × LC, and sire breed as fixed effects; arrival weight as a covariate; and calf nested within the cohort as a random effect. Another mixed linear regression model assessed the association of pathogen shedding with calf ADG from weaning to 238 d with period and sire breed as fixed effects, and pair was nested within cohort as a random effect. A logistic regression model was used to evaluate the likelihood of TUS+ calves shedding a pathogen with pair as a fixed effect. We found an LC × period interaction affecting ADG over period 2 where TUS- calves had increased ADG (1.18 ± 0.02 kg/d) compared with calves with LC = 3 cm² (1.03 ± 0.04 kg/d). However, TUS- calves had similar ADG to calves with LC = 1 to 2 cm² in period 2. Calf ADG was not associated with LC in period 3, and calves weighed 324 ± 37 kg (mean ± SD) at 238 d. In addition, 57% (20/35) of TUS+ calves and 26% (9/35) of TUS- calves shed Pasteurella multocida. We found no association of pathogen shedding with calf ADG, but TUS+ calves were more likely to shed a pathogen. These findings suggest that calves with pneumonia experienced poor growth up to 20 d postweaning, but compensatory gain occurred by 238 d. Furthermore, P. multocida was not associated with growth performance up to 238 d in beef × dairy calves.

News (Medical) associated with Tuspetinib

15 Jul 2025

·www.aptose.com

Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML

SAN DIEGO and TORONTO, July 15, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that it has received an additional advance of US$2.0M from Hanmi Pharmaceutical Co. Ltd. (“Hanmi”), as part of a US$8.5M loan facility agreement with Hanmi (the “Loan Agreement”) announced prior on June 20, 2025 (press release here). To date, Aptose has received an aggregate of US$4.5M under the Loan Agreement. “Tuspetinib in combination with venetoclax and azacitidine (the TUS+VEN+AZA triplet) continues to demonstrate exciting antileukemic activity and safety across genetically diverse populations of newly diagnosed AML patients – including TP53-mutated AML and wildtype AML, representing large AML populations for which there are few treatment options,” said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose. “We are very grateful to Hanmi for its continued support to help advance tuspetinib clinical development and further extend Aptose's ability to fund this important study.” Tuspetinib is a convenient once daily oral agent that potently inhibits targets that drive excessive proliferation and anti-apoptotic mechanisms, including SYK, mutated and wild type forms of FLT3, mutated KIT, JAK1/2, and RSK2 kinases. Yet, TUS maintains a favorable safety profile by avoiding typical toxicity concerns observed with other agents. The ongoing TUSCANY triplet Phase 1/2 study is designed to test various doses and schedules of TUS in combination with standard dosing of azacitidine and venetoclax in newly diagnosed patients with AML who are ineligible to receive induction chemotherapy. At the European Hematology Association Congress in June, Aptose reported early data from the first two dose cohorts that have demonstrated safety, CRs and minimal residual disease (MRD) negativity across patients with diverse mutations (press release here). About Aptose Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company’s lead clinical-stage compound tuspetinib (TUS), is an oral kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit www.aptose.com. Forward Looking Statements This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including statements relating but not limited to, the use of proceeds of the Loan Facility Agreement, the development of tuspetinib, and statements relating to the Company’s plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “should”, “would”, “may”, and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to negotiate a collaboration agreement to jointly develop tuspetinib with Hanmi, our ability to remain compliant with Nasdaq listing requirements and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. For further information, please contact: Aptose Biosciences Inc. Susan Pietropaolo Corporate Communications & Investor Relations 201-923-2049 spietropaolo@aptose.com Released July 15, 2025

License out/in

01 Jul 2025

·www.globenewswire.com

Aptose Upgraded to Trade on OTCQB Market

Aptose will trade under the ticker symbol APTOF and begin trading on OTCQB today, July 1stSAN DIEGO and TORONTO, July 01, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announced today that the Company has been upgraded to list for trading on the OTCQB Market under the ticker “APTOF,” in addition to the Company’s continued listing on the Toronto Stock Exchange (TSX) under the symbol “APS”. Trading on OTCQB begins today, July 1, 2025. The OTCQB Venture Market is for early stage and developing U.S. and international companies. Companies are current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and market information for the company on www.otcmarkets.com. About Aptose Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company’s lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit www.aptose.com. Forward Looking Statements This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements relating to the Company’s plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “should”, “would”, “may”, and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. These risks and uncertainties include, among others: our ability to obtain the capital required for research and operations and to continue as a going concern; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities; unexpected manufacturing defects; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. For further information, please contact Aptose Biosciences Inc.Susan PietropaoloCorporate Communications & Investor Relations201-923-2049spietropaolo@aptose.com

30 Jun 2025

·www.aptose.com

Aptose Announces Deferral of Interest Payment

SAN DIEGO and TORONTO, June 30, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announced that it has entered into an Interest Deferral Agreement (the “Agreement”) with Hanmi Pharmaceutical Co., Ltd. (“Hanmi”), whereby Hanmi has agreed to further defer the interest payment due under the loan facility agreement dated August 27, 2024 (the “2024 Loan Agreement”) between Aptose and Hanmi for the period commencing December 21, 2024 and ending on March 31, 2025 from June 27, 2025 to December 31, 2025 and to defer the interest due under the 2024 Loan Agreement for the period commencing March 31, 2025 and ending on June 30, 2025 to December 31, 2025. About Aptose Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company’s lead clinical-stage compound tuspetinib (TUS), is an oral kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit www.aptose.com. Forward Looking Statements This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including statements relating but not limited to statements relating to the Company’s plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “should”, “would”, “may”, and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to negotiate a collaboration agreement to jointly develop tuspetinib with Hanmi, our ability to remain compliant with Nasdaq listing requirements and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. For further information, please contact: Aptose Biosciences Inc. Susan Pietropaolo Corporate Communications & Investor Relations 201-923-2049 spietropaolo@aptose.com Released June 30, 2025

100 Deals associated with Tuspetinib

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15343

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Adult Acute Myeloblastic Leukemia	Phase 2	United States	Aptose Biosciences, Inc.	11 Mar 2019
Adult Acute Myeloblastic Leukemia	Phase 2	Australia	Aptose Biosciences, Inc.	11 Mar 2019
Adult Acute Myeloblastic Leukemia	Phase 2	Germany	Aptose Biosciences, Inc.	11 Mar 2019
Adult Acute Myeloblastic Leukemia	Phase 2	New Zealand	Aptose Biosciences, Inc.	11 Mar 2019
Adult Acute Myeloblastic Leukemia	Phase 2	Spain	Aptose Biosciences, Inc.	11 Mar 2019
Chronic Myelomonocytic Leukemia	Phase 2	United States	Aptose Biosciences, Inc.	11 Mar 2019
Chronic Myelomonocytic Leukemia	Phase 2	Australia	Aptose Biosciences, Inc.	11 Mar 2019
Chronic Myelomonocytic Leukemia	Phase 2	Germany	Aptose Biosciences, Inc.	11 Mar 2019
Chronic Myelomonocytic Leukemia	Phase 2	New Zealand	Aptose Biosciences, Inc.	11 Mar 2019
Chronic Myelomonocytic Leukemia	Phase 2	Spain	Aptose Biosciences, Inc.	11 Mar 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03850574 (APTIVATE \| TUSCANY, GlobeNewswire) Manual	Phase 1/2	Acute Myeloid Leukemia First line TP53 \| CKB \| FLT3	10	TUS(40mg)+VEN+AZA	gkqnvmwmdp(hvtzcebhqj) = aideiezuga gekpudypyb (msiboukntf )	Positive	12 Jun 2025
				TUS(80mg)+VEN+AZA	gkqnvmwmdp(hvtzcebhqj) = jhnlypfpur gekpudypyb (msiboukntf )
NCT03850574 (APTIVATE \| TUSCANY, EHA2025) Manual	Phase 1/2	Acute Myeloid Leukemia	93	TUS	glnqlyjbkc(pfqinrmhon) = eatgbkfvxd abqingvmvf (teasdoehqu ) View more	Positive	14 May 2025
NCT03850574 (APTIVATE \| TUSCANY, NEWS) Manual	Phase 1/2	Acute Myeloid Leukemia	-	tuspabetinib+venetoclax+azacitidine	zcygbjyugl(pbifsidbhx) = 在两种剂量下，均有多名携带不同突变（包括TP53突变/复杂核型、FLT3野生型）的患者达到了完全缓解（CR）或伴有血液学不完全恢复的完全缓解（CRi），40毫克剂量组中达到CR/CRi的3名患者的最小残留病（MRD）状态均为阴性。 jcbtggvpfr (sqxsgqjdru ) View more	Positive	12 May 2025
NCT03850574 (TUSCANY, Company_Website 1 \| Company_Website 2) Manual	Phase 1/2	Acute Myeloid Leukemia First line TP53 Mutation	4	tuspetinib+venetoclax+azacitidine	ubxvjccfen(aflpapqszs) = zmdkfnjqgb xpjmmbqopt (ksfyaojypb )	Positive	12 Feb 2025
NCT03850574 (APTIVATE, GlobeNewswire) Manual	Phase 1	Acute Myeloid Leukemia FLT3 Mutation	172	Tuspetinib 80 mg (FLT3 mutated)	ztjbaxdnap(sahnwntnkc) = xqeskwghic kbvheglhme (zqttsiwhar ) View more	Positive	09 Dec 2024
				TuspetinibTuspetinib 80 mg (all-comer VEN-naïve)	ztjbaxdnap(sahnwntnkc) = derbthtwtn kbvheglhme (zqttsiwhar )
ASH2024 Manual	Phase 1	Acute Myeloid Leukemia RAS Mutation (Activating) \| FLT3 Mutation \| TP53 Mutation	172	Tuspetinib 80mg	ateukzvxrf(xxhdpvhpsi) = gsdzaskxdh whgwdtqhjr (xethhfunjt )	Positive	09 Dec 2024
				Tuspetinib (VEN-naïve)	ateukzvxrf(xxhdpvhpsi) = kgyjusujrd whgwdtqhjr (xethhfunjt )
NCT03850574 (EHA2024) Manual	Phase 1/2	Acute Myeloid Leukemia	170	Tuspetinib (TUS) 20-200mg	yflowbxpjy(wwyuhtaafg) = fqxuuxlxdd fcdiuhtfcg (ffezkpnuch ) View more	Positive	14 May 2024
				Tuspetinib Venetoclax/Venetoclax (VEN) 400mg	uxevecmpdd(zusynagcbh) = nmrymporpf izxnjfgkit (beeykrdhgp ) View more
NCT03850574 (APTIVATE, ASH2023) Manual	Phase 1/2	Acute Myeloid Leukemia	100	Tuspetinib 20mg to 200mg (Parts A/B)	dfvnlhirwl(fyrkoubnot) = One patient experienced a DLT (Grade 3 muscular weakness) at 200 mg which demonstrated partial improvement at the time of treatment discontinuation (9 days after AE onset). vuuqiizgqr (wvjulbwqra ) View more	Positive	09 Dec 2023
				Tuspetinib 120 mg (Part C)
NCT03850574 (APTIVATE, GlobeNewswire) Manual	Phase 1/2	Acute Myeloid Leukemia FLT3 Mutation	117	Tuspetinib	xiybrmrvyn(dftudgceqz) = eszsxiwnfo szqijindns (kbpihlcizq ) View more	Positive	09 Dec 2023
				Tuspetinib 80 mg + Venetoclax 200 mg	xiybrmrvyn(dftudgceqz) = aaiyilzgjy szqijindns (kbpihlcizq )
NCT03850574 (EHA2022)	Phase 1/2	Acute Myeloid Leukemia	-	HM43239	gwfsoocfij(rbptbfhnrt) = tzsuagabbb vposwnohpp (imsvwcpsyc ) View more	-	12 May 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Tuspetinib

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation